retatrutide nonalcoholic steatohepatitis nash trial fatty liver disease Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming retatrutide nonalcoholic steatohepatitis nash trial

Diet and Exercise Support: Alongside the medication, Watson provides customized nutrition plans and fitness advice to complement the treatment

The rise of GLP-1 weight loss medications, such as Wegovy and Ozempic are revolutionizing weight management

The American Journal of Sports Medicine, 48 (8), 1916-1928

ADA Standards of Care in Diabetes

Image credit: Tetiana_Kryvous/Shutterstock.com A new study in the Medical Journal of Australia examines the use of glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) in reproductive-age women in Australia to effectively manage type 2 diabetes mellitus, along with contraception overlap and pregnancy incidence in this population

OA-NPs@OA exhibited superior effects to free OA and Calcipotriol Ointment